Headlines about Lexicon Pharmaceuticals (NASDAQ:LXRX) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.037175188889 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern’s analysis:
- Amgen Inc. (AMGN) is at $170.07 per share and Lexicon Pharmaceuticals, Inc. (LXRX) is listed at $14.22 - Stocks Gallery (stocksgallery.com)
- Watching the Tape Move for Lexicon Pharmaceuticals Inc (LXRX) and United Therapeutics Corp (UTHR) - FLBC News (flbcnews.com)
- Notable Monday Option Activity: LXRX, NFLX, PRLB (nasdaq.com)
- 1281 Shares Of Lexicon Pharmaceuticals, Inc. (LXRX) bought By AMOUYAL PHILIPPE - Economic News (economicsandmoney.com)
- What the Chart Means for Lexicon Pharmaceuticals, Inc. (LXRX) - Economic News (economicsandmoney.com)
Shares of Lexicon Pharmaceuticals (LXRX) traded up 0.71% during midday trading on Thursday, hitting $14.22. The stock had a trading volume of 76,715 shares. Lexicon Pharmaceuticals has a 12 month low of $13.41 and a 12 month high of $19.62. The stock’s market cap is $1.50 billion. The stock’s 50-day moving average is $15.61 and its 200-day moving average is $15.44.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The company had revenue of $12 million during the quarter, compared to analysts’ expectations of $18.34 million. During the same quarter in the previous year, the firm posted ($0.37) EPS. The firm’s revenue was down 40.3% compared to the same quarter last year. Equities analysts anticipate that Lexicon Pharmaceuticals will post ($1.45) EPS for the current year.
LXRX has been the subject of a number of analyst reports. BidaskClub raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, June 14th. HC Wainwright set a $27.00 price target on Lexicon Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 3rd. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Finally, Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $27.00.
TRADEMARK VIOLATION WARNING: This news story was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/08/24/lexicon-pharmaceuticals-lxrx-receives-coverage-optimism-rating-of-0-20.html.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
